Drug Developers Expecting Significant Clinical and Economic Benefits by Targeting Newest Drug Therapies

PALM BEACH, Florida, July 11, 2018 /PRNewswire/ --

MarketNewsUpdates.com News Commentary 

Clinical trial development is advancing ways to support sponsors and partnerships as biotech and pharmaceutical companies race to find, develop and deliver immuno-oncology (IO) therapies to the growing number of patients who await them. The biotech and big pharma industries are paying attention to the fact that over 3.65 million people every year are reaching retirement age in the U.S. not expecting to slow down until at least 2029. As American "baby boomers" reach the golden retirement age, the impact of the aging population is expected to drive national healthcare expenditures as well as company revenues much higher. According to the Centers for Medicare and Medicaid Services, in 2016, U.S. healthcare expenditures topped $3.4 trillion; this is $10,348 per person, and the figure is expected to grow 5.5% annually through 2026. The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process causing an uptick in clinical trial activities and advanced drug therapy developments. Active companies in the markets today include: Moleculin Biotech, Inc. (NASDAQ: MBRX), Celgene Corporation (NASDAQ: CELG), Acceleron Pharma Inc. (NASDAQ: XLRN), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), MediciNova, Inc. (NASDAQ: MNOV).

Moleculin Biotech, Inc. (NASDAQ: MBRX) BREAKING NEWS: Moleculin Biotech, a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has formed Moleculin Australia Pty. Ltd., a wholly-owned subsidiary to oversee preclinical development in Australia.

"The Australian government provides a very aggressive incentive for research and development carried out in their country," commented Walter Klemp, Chairman and CEO of Moleculin. "For companies like Moleculin with less than $20,000,000 AUD group turnover, it can amount to a rebate of up to 43.5% of qualified R&D expenditures. Having an Australian subsidiary provides a great opportunity to speed up preclinical development and reduce the overall cost of our continued drug development efforts." Read this and more news for Moleculin Biotech at: http://www.marketnewsupdates.com/news/mbrx.html